Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amilomotide

Next Previous
Drug Profile

Amilomotide

Alternative Names: Alzheimer's disease virus-like particle-based vaccine - Novartis; Alzheimer's disease VLP-based vaccine - Novartis; Beta-amyloid protein immunotherapy - Novartis; CAD 106; Immunodrug™ for Alzheimer's disease - Novartis

Latest Information Update: 20 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; Novartis
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants; Virus-like particle vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Discontinued Hypersensitivity; Rheumatoid arthritis

Most Recent Events

  • 26 Jul 2021 Adverse events and efficacy data from a phase II/III trial in Alzheimer's disease presented at the Alzheimer's Association of International Conference (AAIC-2021)
  • 08 Jan 2020 Discontinued - Phase-II for Alzheimer's disease in Switzerland, Norway, Sweden, Spain, Netherlands, Italy, Germany, Canada (IM)
  • 15 Jul 2019 Discontinued - Phase-II/III for Alzheimer's disease in USA, Finland, Belgium, United Kingdom, Finland (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top